Dr. Claude Bertrand serves as the President of ARIIS. Dr. Bertrand served as the Chief Scientific Officer and Executive Vice President of Research & Development at S.A. until January 2, 2016. Dr. Bertrand served as an Executive Vice President of Ipsen S.A. since November 2, 2009. He was the Chief Scientific Officer of IPSEN Pharma Dr. Bertrand joined the allergy and asthma unit at Ciba-Geigy (later Novartis). Since 1996, he served at the Inflammatory disease Unit at Roche Bioscience where he served as the Head of the in vivo pharmacology group and was responsible for supporting projects in arthritis and respiratory diseases. During that time, he co-ordinated chemokine research for Roche Global. Since 1999, he also served as a Director of Pharmacology for Inflammation, GI and Pain at the Fresnes (France) R&D site of Parke-Davies, which was a part of Pfizer. Since 2004, Dr. Bertrand served at AstraZeneca as a Vice-President of Discovery for Respiratory & Inflammation Research at Alderley Park and since 2005, he served as a Global Vice President for Respiratory & Inflammation Research Area and overseeing research activities. Since June 2009, he served at the Development organisation of Astra Zeneca as a Senior Vice President of Launched and Established brands. He has been an Independent Director of ABIVAX S.A. since March 11, 2014.He also serves on the Board of INSERM and Eclosion SA. He has 28 years of experience in the pharma industry (Roche, Pfizer, Astra Zeneca) in roles spanning the breadth of drug discovery, development and life cycle management. He graduated in Pharmacy (Pharm.D.) from Strasbourg University in France and obtained his PhD in Strasbourg (France) with research in the fields of immuno-pharmacology and neurogenic inflammation. He did a 2-year post-doctoral appointment at University of California, San Francisco with Prof. Jay A. Nadel.

Immuno-pharmacology and neurogenic inflammation